Loading, please wait...
The goal of this program is to update on the current guidelines on compounding hazardous sterile drugs, including USP 800.
***Please note: this course is 2 hours of CE credit***
To access the video after registration, please click the "+" sign to the left of the program title listed below in light blue.
CE Hours
4.00
CE Units
0.400
Activity Type
- Application
Target Audience(s)
- Pharmacists
- Pharmacy Technicians
Accreditation(s)
|
Texas Tech University Health Sciencies Center Jerry H. Hodge School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
To receive credit you must watch the recorded webinar and complete the post-test. You must receive a minumum of 70% on the post-test at which time you will be prompted to complete a program evaluation form.
|
Please choose a Fee Type from the Drop Down Menu Below:
I am a
|
Objectives
- Discuss the regulations and organizations involved in the handling of hazardous drugs for sterile compounding.
- Describe the role of USP <800> in compounding hazardous drugs and topics covered.
- Identify specific engineering controls specific for hazardous compounding.
- Differentiate the cleaning processes and aseptic manipulations in BSCs vs. horizontal LAFW.
- Compare PPE needed for compounding hazardous drugs to non-hazardous compounding
- Calculate BSA and chemotherapy doses.
Speaker(s)/Author(s)
|
Mikala Conatser, Pharm.D. Disclosure : The presenter has no relevant conflict of interest related to this presentation. The speaker has no relevant financial relationship(s) with ineligible companies to disclose with regard to this presentation. |
Activity Number
0096-0000-21-091-H07-P
Release Date:
Sep 21, 2021
Credit Expiration Date:
Sep 21, 2024
CE Hours
2.00
Fee
$20.00
Objectives
- Discuss the regulations and organizations involved in the handling of hazardous drugs for sterile compounding
- Describe the role of USP <800> in compounding hazardous drugs and topics covered
- Identify specific engineering controls specific for hazardous compounding
- Differentiate the cleaning processes and aseptic manipulations in BSCs vs. horizontal LAFW
- Compare PPE needed for compounding hazardous drugs to non-hazardous compounding
- Calculate appropriate volumes for chemotherapy based on given doses.
Speaker(s)/Author(s)
|
Mikala Conatser, Pharm.D. Disclosure : The presenter has no relevant conflict of interest related to this presentation. The speaker has no relevant financial relationship(s) with ineligible companies to disclose with regard to this presentation. |
Activity Number
0096-0000-21-091-H07-T
Release Date:
Sep 21, 2021
Credit Expiration Date:
Sep 21, 2024
CE Hours
2.00
Fee
$20.00